27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. 4 key findings →
Participants: 577 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Twelve months' treatment with doxycycline or rifampin, alone or in combination, has no beneficial effects on cognition or function in AD. 5 key findings →
Design: randomized controlled trial Participants: 305 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As the physiological impact of chronic stress is difficult to study in humans, naturalistic stressors are invaluable sources of information in this area. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using DSM-IV criteria, 55 of 280 patients (19.6%) had delirium versus 17.6% using the CAM. 1 key finding →
Participants: 280 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DSD is linked to adverse outcomes, compared to dementia alone, like longer hospitalisation [3], mortality [3, 4], functional decline [3] and need for residential care [3]. 4 key findings →
Design: systematic review Participants: 64 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Prevention of dementia represents a public health priority. 3 key findings →
Design: longitudinal study Participants: 180 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sensitive and specific instruments are required to screen for cognitive impairment (CI) in busy clinical practice. 4 key findings →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Most patients received physical assessments, including mobility (89 %), continence (84 %) and pressure sore risk (87 %); however assessment of pain (75 %), and particularly functioning (36 %) was poor. 3 key findings →
Participants: 660 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We studied the clinical features, pathology, and molecular genetics of a family (Mo) with an autosomal dominant disinhibition, frontal lobe dementia, parkinsonism, and amyotrophy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A consequence of our progressively ageing global population is the increasing prevalence of worldwide age-related cognitive decline and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Previous studies have indicated a prevalence of dementia in older admissions of ∼42% in a single London teaching hospital, and 21% in four Queensland hospitals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
An international expert panel convened to evaluate nutrition-based approaches to brain health and dementia prevention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The normal on and off switching of the PI3-K (phosphoinositide 3-kinase)/Akt pathway, particularly by its major activators insulin and IGF-1 (insulin-like growth factor-1), is a powerful integrator of physiological responses rudimentary to successful aging. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 47 adults aged 55+ years were recruited (50% male; 49% aged 60-69 years; 28% aged above 70 years), and 26 HCPs were involved, comprising dietitians (n = 8); geriatricians (n = 6); clinical therapists (n = 4); and nurses, pharmacists, catering managers and meal delivery service coordinators (n = 2 each). 5 key findings →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Within the 440 included surveys, respondents particularly over-estimated frailty prevalence in older hospitalised patients, with two-thirds choosing between 41 and 80% prevalence, when the literature suggests only 23-46%, but paradoxically underestimated the frequency of frailty in people with delirium (more than three quarters of responses across 21-80%; literature suggests 71-93%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study provides validated conversion tables between the Q mci screen and two widely-used cognitive instruments, to support the use of the Q mci screen in research (facilitating cross-instrument comparability and harmonization across studies), and clinical settings (determining eligibility for disease-modifying therapies). 2 key findings →
Participants: 101 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Twenty-five studies met the inclusion criteria. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The logic model and summary results explain in detail how this dementia palliative care service undertook activities relating to person-centred care, carer support, end-of-life care, accessible care, timely care, and integrated care. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results support the hypothesis that engaging in physical activity can compensate for urban-rural differences in cognitive performance in ageing. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →